Paper22914404
Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial.
Grimm C and 9 others. Obstet Gynecol, 2012. Cited by 108 papers, by iCite.
Cite this record
ConductScience Library. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Papers, record 22914404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22914404
- Disease
- cervical intraepithelial neoplasia38 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoquinolines | Major topic |
| Antineoplastic Agents | Major topic |
| Uterine Cervical Neoplasms | Major topic |
| Uterine Cervical Dysplasia | Major topic |
| Adult | |
| Female | |
| Humans | |
| Imiquimod | |
| Papillomavirus Infections | |
| Remission Induction | |
| Treatment Outcome | |
| Viral Load | |
| Young Adult |
Source PubMed
Trials7
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00941252 | ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02329171 | Imiquimod Treatment of CIN Lesions | Background | ClinicalTrials.gov | |
| NCT02669459 | Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol | Results | ClinicalTrials.gov | |
| NCT02917746 | Imiquimod Treatment of High-grade CIN | Background | ClinicalTrials.gov | |
| NCT03233412 | Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions | Results | ClinicalTrials.gov | |
| NCT04859361 | Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ | Background | ClinicalTrials.gov | |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial | Background | ClinicalTrials.gov |
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882092 | From Active Compound to Target Epithelium: Local Delivery, Preclinical Model Validity, and Clinical Endpoint Interpretation in Topical Therapy for HPV-Associated Lower Genital Tract Disease-A Narrative Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/42882092 | PubMed |
| 41107612 | Topical vaginal drug therapy in cervical cancer management: a review of clinical trials and preclinical evidence. | Med Oncol | 2025 | https://conductscience.org/library/papers/41107612 | PubMed |
| 40632662 | Improving imiquimod use in cervical high-grade squamous intraepithelial lesions: A qualitative study. | Acta Obstet Gynecol Scand | 2025 | https://conductscience.org/library/papers/40632662 | PubMed |
| 40556801 | 'ARVs is for HIV and cream is for HPV or precancer:' Women's perceptions and perceived acceptability of self-administered topical therapies for cervical precancer treatment: a qualitative study from Kenya. | Ecancermedicalscience | 2025 | https://conductscience.org/library/papers/40556801 | PubMed |
| 40530116 | "Prime and pull" vaccination strategy for treatment of cervical pre-cancer: not quite ready for prime time. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/40530116 | PubMed |
| 40362199 | Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362199 | PubMed |
| 40282913 | Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40282913 | PubMed |
| 40034605 | Transient bacteraemia secondary to imiquimod use as a treatment for cervical high-grade squamous intraepithelial lesions - A case report. | Case Rep Womens Health | 2025 | https://conductscience.org/library/papers/40034605 | PubMed |
| 40005442 | The Role of Medical Therapies in the Management of Cervical Intraepithelial Neoplasia: A Narrative Review. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40005442 | PubMed |
| 39950806 | Sexually transmitted human papillomavirus and related sequelae. | Clin Microbiol Rev | 2025 | https://conductscience.org/library/papers/39950806 | PubMed |
| 39920276 | Dendritic cell maturation in cancer. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/39920276 | PubMed |
| 39065561 | Imiquimod-Loaded Nanosystem for Treatment Human Papillomavirus-Induced Lesions. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39065561 | PubMed |
| 39021542 | Men's perceptions and perceived acceptability of their female partner's use of self-administered intravaginal therapies for treatment of cervical precancer in Kenya. | Ecancermedicalscience | 2024 | https://conductscience.org/library/papers/39021542 | PubMed |
| 38672691 | Imiquimod Is Effective in Reducing Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38672691 | PubMed |
| 38585806 | Perceived acceptability of self-administered topical therapy for cervical precancer treatment among women undergoing cervical cancer screening in Kenya. | medRxiv | 2024 | https://conductscience.org/library/papers/38585806 | PubMed |
| 38556619 | Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial. | BJOG | 2025 | https://conductscience.org/library/papers/38556619 | PubMed |
| 38553612 | YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells. | Apoptosis | 2024 | https://conductscience.org/library/papers/38553612 | PubMed |
| 38532929 | "There is nothing that can prevent me from supporting her:" men's perspectives on their involvement and support of women's use of topical therapy for cervical precancer treatment in Kenya. | Front Oncol | 2024 | https://conductscience.org/library/papers/38532929 | PubMed |
| 38420364 | Effect of different interventions on the treatment of high-risk human papillomavirus infection: a systematic review and network meta-analysis. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/38420364 | PubMed |
| 38254888 | Human Papillomavirus Infections and the Role Played by Cervical and Cervico-Vaginal Microbiota-Evidence from Next-Generation Sequencing Studies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38254888 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| IMIQUIMOD | CHEMBL1282 | Results | 3 | https://conductscience.org/library/drugs/CHEMBL1282 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22914404
GET https://conductscience.org/api/papers/v1/22914404/cited_by?page=2